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Abstract: The study evaluated substrate cleavage product(s) generated by three botulinum 
neurotoxin serotype A (BoNT/A) medicinal drug products utilizing a novel and highly 
specific, light-chain activity, high-performance liquid chromatography (LCA-HPLC) 
method. Samples were reacted with a commercially available BoNT/A fluorescent 
substrate derived from the SNAP-25 sequence. Reaction products were separated by 
reversed-phase HPLC. The method detected an atypical cleavage pattern by one of the 
formulated drug products. IncobotulinumtoxinA produced two cleavage fragments rather 
than the single fragment typically generated by BoNT/A. Identification confirmed the 
secondary cleavage at a position corresponding to SNAP-25 Arg198–Ala199 (normal 
BoNT/A cleavage is Gln197–Arg198). Arg198–Ala199 is also the cleavage site for trypsin 
and serotype C toxin. Normal cleavage was observed for all other BoNT/A drug product 
samples, as well as 900-kD and 150-kD bulk toxin BoNT/A. The reason for this 
unexpected secondary cleavage pattern by one formulated BoNT/A drug product is 
unknown. Possible explanations include a contaminating protease and/or damage to the 
150-kD type-A toxin causing nonspecific substrate recognition and subsequent cleavage 
uncharacteristic of type-A toxin. The BoNT/A drug products were also analyzed via the 
LCA-HPLC assay using a commercial BoNT/C fluorescent substrate derived from the 
syntaxin sequence. Cleavage of the serotype C substrate by incobotulinumtoxinA was also 
confirmed whilst neither of the other drug products cleaved the syntaxin substrate. 
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1. Introduction 
Seven serotypes (A to G) of Clostridium botulinum are known. Each serotype synthesizes a 150-kD 
neurotoxin (BoNT) along with a group of nontoxic neurotoxin-associated proteins (NAPs) that form 
complexes [1]. BoNT is a zinc-endopeptidase that is composed of a 100-kD heavy-chain and a 50-kD 
light-chain, connected by a disulfide bond. The heavy-chain is responsible for binding (C-terminal 
domain) and translocation (N-terminal domain), whereas the light-chain is responsible for proteolytic 
activity. The light-chain of each serotype specifically cleaves one or more soluble N-ethylmaleimide—
sensitive factor attachment receptors (SNAREs). The endopeptidase activities of the toxins are unique 
in that they require the reduction of the disulfide bond between the light and heavy chains in order for 
enzymatic activity to occur. Each serotype cleaves selectively at a specific peptide bond of a specific 
substrate. For example, the light-chain of BoNT serotype A (BoNT/A) specifically cleaves SNAP-251–206 
at position Gln197–Arg198 [2]. This specific cleavage is an intrinsic property of the serotype.  
Serotype A has been formulated into several drug products for therapeutic treatment of various 
disorders. The formulated drug products differ considerably in both drug substance and drug product 
composition (see Table 1).  
Table 1. BoNT/A drug product composition. 
Non-proprietary 
Name 
Brand 
Name 
Labeled Potency 
(LD50) 
Toxin Excipients 
onabotulinumtoxinA BOTOX
® 100  Units 
BoNT/A 
900-kD complex 
0.5 mg HSA 
a 
0.9 mg NaCl 
abotulinumtoxinA Dysport
® 500  units 
BoNT/A 
300/500-kD 
b complex 
0.125 mg HSA 
a 
2.5 mg Lactose 
incobotulinumtoxinA Xeomin
® 100  Units 
BoNT/A 
150-kD 
1 mg HSA 
a 
4.7 mg Sucrose 
a Human serum albumin. 
b Ipsen Biopharm Limited reported molecular weight range of the complex. 
Recently the drug products have been assigned non-proprietary (USAN) names to avoid confusion 
due to brand names and to emphasize the non-interchangeability of units. However, physicochemical 
evaluations that might offer functional insight into differences have thus far been limited. 
It is important to note that it is the SNARE cleavage (described above) that ultimately produces the 
desired therapeutic effect by inducing regional disruption of neuronal stimulation of an organ   
(e.g., muscle or sweat gland). Due to the potent nature of the toxin, extremely small therapeutic 
concentrations are sufficient; typically nanograms per finished drug product vial. The inherent 
difficulties in analyzing nanogram quantities of formulated drug substance have relegated most 
comparisons to the clinical setting. However, compared to physicochemical techniques, clinical 
readouts can be insensitive while providing limited mechanistic information. What has been lacking is Toxins 2010, 2  
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a highly-sensitive endopeptidase activity assay that is not subject to matrix interference due to 
excipients and allows simultaneous characterization of cleavage specificity. 
Existing endopeptidase assays, such as spectrophotometric assays, are insufficiently sensitive to 
measure drug product concentrations and are subject to drug product matrix interferences. For 
example, BoNT/A light-chain activity methods utilizing fluorescence resonance energy transfer 
(FRET) substrates typically measure a change in fluorescent signal directly from the reaction solution. 
The total fluorescence of the reaction solution, which includes intrinsic fluorescence due to reaction 
buffer components and toxin formulation excipients, is measured before and after substrate cleavage. 
An increase or decrease in fluorescence will result, depending on the FRET pair used. This change in 
fluorescent signal due to cleavage is non-specific and often small in relation to the background signal, 
resulting in poor sensitivity. Immunoassays represent another technique employed for measuring 
endopeptidase activity. These assays rely on the availability of special reagents (i.e., high-affinity 
antibodies for each cleavage product) to achieve specificity [3] and are incompatible with many 
commonly used formulation excipients. The result is that most assays currently used are inconvenient, 
product specific and insensitive, usually requiring many product vials to accomplish a single test that 
results in only limited information. 
The light-chain activity high-performance liquid chromatography (LCA-HPLC) method developed 
and applied here incorporates a light-chain reaction procedure using a commercially available BoNT/A 
FRET substrate derived from the SNAP-25 sequence coupled with a reversed-phase (RP)-HPLC 
analysis procedure to detect and quantitate the fluorescently labeled reaction product(s). The method is 
unique in that the RP-HPLC analysis eliminates matrix interferences by separating the cleaved 
substrate products from the non-cleaved substrate, other reaction reagents, and product formulation 
components, thereby significantly increasing the signal-to-noise ratio. This method provides   
single-vial sensitivity along with high throughput due to the HPLC automation. Additionally, because 
the method requires only substrate and no product-specific antibodies or reagents, it provides the 
opportunity to evaluate and compare drug products; for example assessing the effects of formulation 
excipients, manufacturing processes, and other parameters on light-chain activity and stability. 
Another significant advantage of this procedure is the ability to separate, detect and quantify 
distinct light-chain cleavage products. While methods exist to measure the light-chain activity of 
BoNTs [4,5], this is the first method (to our knowledge) to selectively determine, as a routine part of 
the assay, the actual cleavage product(s) generated by formulated BoNT/A drug products. The 
adaptable nature of the method also allowed simple substitution of an additional substrate derived from 
the syntaxin sequence, further extending the range of potential characterization to serotype C 
characterization. The straightforward substitution of substrates extends the utility as an identification 
test [6]. 
2. Materials and Methods 
The present study compared the light-chain enzymatic activities of three BoNT/A drug products: 
onabotulinumtoxinA (BOTOX
®, Allergan, Inc.; Irvine, CA, USA), incobotulinumtoxinA (Xeomin
®, 
Merz Pharmaceuticals; Frankfurt, Germany), and abotulinumtoxinA (Dysport
®, Ipsen Biopharm 
Limited; Wrexham, UK). All drug products were stored according to label instructions and tested Toxins 2010, 2  
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within expiration dating. The light-chain activity and cleavage pattern of these BoNT/A products were 
assessed using the novel LCA-HPLC method reported here with BoNT/A substrate (SNAPtide
®520; 
List Biological Laboratories, Inc.; Campbell, CA, USA). SNAPtide
®520 sequence: Abz Thr D-Arg Ile 
Asp Gln Ala Asn Gln Arg Ala Thr Lys Nle Lys Dnp; where Abz = o-Aminobenzoic acid (FRET pair 
fluorophore) and Dnp = 2,4-Dinitrophenyl (FRET pair quencher). 
BoNT/A cleavage fragment (designated as SNAPtide
®529 by List Biological Laboratories, Inc.) 
was utilized to identify retention time of the fragment. 
900-kD BoNT/A toxin complex (supplied by Allergan, Inc.; Irvine, CA, USA) and 150-kD 
BoNT/A holotoxin (supplied by Metabiologics, Inc.; Madison, WI, USA) were used to characterize 
BoNT/A unformulated bulk toxin cleavage.  
Commercially available BoNT/C FRET substrate (SYNTAXtide
®560; List Biological Laboratories, 
Inc.; Campbell, CA, USA) was utilized to assess type-C cleavage. Because of the RP-HPLC   
reaction-product readout, no modification to the method was necessary in order to observe the reaction 
products generated using the SYNTAXtide
®560 substrate.  
Trypsin (TrypZean, Sigma-Aldrich Corp.; St. Louis, MO, USA) was utilized to identify 
characteristic trypsin cleavage while Serotype C light-chain (List Biological Laboratories, Inc.; 
Campbell, CA, USA) was obtained for type-C cleavage generation. 
2.1. Enzymatic (Light-chain) Reaction Conditions 
Each BoNT/A product vial was reconstituted with 1 mL of digestion buffer (see Table 2).  
Table 2. Reaction solutions. 
Digestion buffer  0.5 mM ZnCl2, 2 mM DTT 
a, 0.05% Tween 20 in 50 mM HEPES, pH 7.4 
Substrate  200 µM SNAPtide
®520 
b prepared in sterile water for injection 
a  DTT = Dithiothreitol. 
b  List Biological Laboratories, Inc., supplied through Calbiochem, San Diego, CA, USA   
(Cat #567333). 
A 0.45 mL aliquot of each reconstituted sample was transferred to separate reaction tubes. The 
samples were then heated at 37 °C for 30 minutes (reduction step). After completion of the reduction 
step, 25 µL of 200 µM SNAPtide
®520 was then added to each tube (equivalent to 10.5 µM 
SNAPtide
®520). For the experiment using the SYNTAXtide
®560 substrate (type-C), a volume of 
50  µL of 200 µM SYNTAXtide
®560 was added to each reaction tube (equivalent to 20  µM 
SYNTAXtide
® 560). 
The reaction samples were then incubated at 30 °C for 20 hours (digestion step). At the completion 
of the digestion step, 25 µL of 5% trifluoroacetic acid (TFA) was added to each tube to stop the 
reaction. The contents of each tube were then transferred to HPLC vials for analysis. 
2.2. HPLC Analysis 
The fluorescently labeled cleavage product(s) were separated and detected via an RP-HPLC method 
using a Waters 2695 XE Separations Module and a Waters 2475 Multi λ Fluorescence Detector (see 
Table 3 for HPLC parameters).  Toxins 2010, 2  
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Table 3. HPLC parameters. 
Column  Waters Symmetry300™ C18, 3.5 µm, 4.6 × 150 mm (P/N: 186000197) 
Column Temperature  35 °C 
Injection Volume  25 µL 
Flow  1 mL/min 
Detection  Excitation λ = 322 nm; Emission λ = 420 nm 
The samples were eluted using a gradient program (see Table 4) with a mobile phase consisting of 
0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B). The data were collected and analyzed via 
Waters Empower™ Pro software (Waters Corp.; Milford, MA, USA). 
Table 4. HPLC Gradient Program. 
Time (min)  %A  %B 
0 90  10 
5 90  10 
13 85 15 
18 5 95 
20 5 95 
21 90 10 
30 90 10 
3. Results and Discussion 
The LCA-HPLC method demonstrated excellent single-vial sensitivity and resolution of the 
fluorescently labeled BoNT/A cleavage fragment (designated as SNAPtide
®529 by List Biological 
Laboratories, Inc.) when analyzing onabotulinumtoxinA, abotulinumtoxinA and incobotulinumtoxinA 
drug products. See Figure 1 for an example chromatogram of onabotulinumtoxinA. No formulation or 
reaction component interferences were observed.  
Figure 1. Chromatogram of onabotulinumtoxinA (BOTOX
® Lot #C1550C1) reaction 
solution (SNAPtide
®520 substrate) exemplifying generation of the 529 fragment peak.  
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An excipient peak, identified as N-Acetyl-tryptophan (NAT), exists in all the commercial product 
chromatograms but is readily resolved from the reaction products. NAT is used as a stabilizer in human 
serum albumin (HSA). OnabotulinumtoxinA, abotulinumtoxinA, and incobotulinumtoxinA drug 
products all contain HSA.  
All BoNT/A drug products tested generated the expected BoNT/A substrate cleavage product. 
However, when analyzed using the LCA-HPLC method, the incobotulinumtoxinA drug product 
generated two (2) substrate cleavage products (see Figure 2).  
Figure 2. Chromatogram of incobotulinumtoxinA (Xeomin
® Lot #408012) reaction 
solution (SNAPtide
®520 Substrate) exemplifying generation of the 529 fragment peak and 
the atypical “T fragment” peak. 
 
Under identical reaction conditions, onabotulinumtoxinA generated only the expected BoNT/A 
substrate cleavage product (see Figure 1), as did abotulinumtoxinA (see Figure 3).  
Figure 3. Chromatogram of abotulinumtoxinA (Dysport
® Lot #589AB) reaction solution 
(SNAPtide
®520 Substrate) exemplifying generation of the 529 fragment peak. 
 
F
l
u
o
r
e
s
c
e
n
c
e
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
9.00
10.00
Minutes
8.00 8.50 9.00 9.50 10.00 10.50 11.00 11.50 12.00 12.50 13.00 13.50 14.00 14.50 15.00 15.50 16.00
5
2
9
 
-
 
9
.
9
0
2
T
 
F
r
a
g
m
e
n
t
 
-
 
1
1
.
1
7
0
N
A
T
 
-
 
1
5
.
0
0
9
F
l
u
o
r
e
s
c
e
n
c
e
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
Minutes
8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00
5
2
9
 
-
 
1
0
.
0
5
2Toxins 2010, 2  
 
 
2204
In addition, samples of bulk 150-kD BoNT/A and 900-kD BoNT/A only generated the single 
expected BoNT/A substrate cleavage product [7](see Figures 4 and 5). 
Figure 4. Chromatogram of 150-kD BoNT/A reaction solution (SNAPtide
®520 Substrate) 
exemplifying generation of the 529 fragment peak. 
 
Figure 5. Chromatogram of 900-kD BoNT/A reaction solution (SNAPtide
®520 substrate) 
exemplifying generation of the 529 fragment peak. 
 
The secondary cleavage product observed from incobotulinumtoxinA was identified by HPLC 
retention time as the SNAPtide
®529 fragment plus one amino acid (see Figures 6 and 7).  
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Figure 6. Chromatogram of synthesized samples of SNAPtide
®529 and “T fragment” for 
retention time identification. Elution positions match the generated cleavage fragments. 
 
Figure 7. BoNT/A Reaction Scheme with SNAPtide
®520 Substrate. 
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This was accomplished by injecting a range of synthesized SNAPtide
®520 fragments along with the 
SNAPtide
®529 fragment and comparing the retention times. The sequence for the SNAPtide
®520 
substrate is given in the List Biological Laboratories, Inc., patent [8]. BoNT/A specifically cleaves 
SNAP-251–206 at position Gln197–Arg198, while the secondary cleavage product is the result of 
cleavage of SNAP-251–206 at Arg198–Ala199. Trypsin also cleaves at Arg198–Ala199 (data on file); 
hence, this secondary cleavage product observed from incobotulinumtoxinA was termed the   
“T fragment” for convenience. It should be noted that this is also the cleavage site for serotype C toxin 
(BoNT/C)[9]. 
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A control reaction was run on the incobotulinumtoxinA product, without the SNAPtide
®520 
substrate, to elucidate whether the observed peak was indeed due to the cleavage of the substrate or 
whether it was an extraneous peak due to the formulation ingredients or to a formulation matrix 
interaction with a reaction component (see Figure 8).  
Figure 8. Chromatogram of incobotulinumtoxinA (Xeomin
® Lot #408012) reaction 
solution without the addition of substrate demonstrating drug product generates no peaks in 
the absence of substrate. 
 
No peak eluting at the retention time of the “T fragment” peak was observed in this control reaction, 
confirming that the “T fragment” peak generated by incobotulinumtoxinA was indeed due to 
enzymatic cleavage of SNAPtide
®520 substrate. 
Peak area results for five incobotulinumtoxinA drug product lots along with a onabotulinumtoxinA 
drug product lot are given in Figure 9. All incobotulinumtoxinA drug products assayed demonstrated 
significant levels of secondary cleavage.  
Figure 9. Peak area results for incobotulinumtoxinA (Xeomin
®) samples compared to 
onabotulinumtoxinA (BOTOX
®) control. Samples analyzed by LCA-HPLC using the 
SNAPtide
®520 substrate. Test Date: April 2007, all samples tested within expiry. 
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When onabotulinumtoxinA drug product was analyzed without reduction, i.e., DTT omitted from 
the reaction buffer, no substantial reaction products were observed (see Figure 10).  
Figure 10. Chromatogram of onabotulinumtoxinA (BOTOX
® Lot #C1550C1) reaction 
solution without the reduction step (no DTT added) demonstrating the 529 peak is not 
generated from by onabotulinumtoxinA from the SNAPtide
®520 substrate without reduction. 
 
However, when incobotulinumtoxinA drug product was analyzed without the reduction step (no 
DTT), the secondary cleavage product (“T fragment”) was still generated (see Figure 11), indicating 
reduction is not necessary for this cleavage. No SNAPtide
®529 fragment (primary BoNT/A cleavage 
product) was detected when testing incobotulinumtoxinA drug product under non-reduced conditions. 
Figure 11. Chromatogram of incobotulinumtoxinA (Xeomin
® Lot #408012) reaction 
solution without the reduction step (no DTT added) exemplifying the “T fragment” peak is 
generated by incobotulinumtoxinA from the SNAPtide
®520 substrate without reduction. 
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When reacted with the SYNTAXtide
®560 substrate (serotype C substrate), incobotulinumtoxinA 
drug product generated a major peak eluting at 3.5 minutes along with two (2) small peaks eluting at 
10.3 and 15.7 minutes, respectively (see Figure 12).  
Figure 12. Chromatogram of incobotulinumtoxinA (Xeomin® Lot #708041) reaction 
solution with SYNTAXtide
®560 substrate (serotype C substrate) demonstrating the 
incobotulinumtoxinA BoNT/A drug product cleaves serotype C substrate. 
 
Neither onabotulinumtoxinA or abotulinumtoxinA generated any cleavage products when reacted 
with the SYNTAXtide
®560 substrate (see Figures 13 and 14).  
Figure 13. Chromatogram of onabotulinumtoxinA (BOTOX® Lot #408012) reaction 
solution with SYNTAXtide
®560 substrate (serotype C substrate) exemplifying the 
onabotulinumtoxinA BoNT/A drug product does not cleave serotype C substrate. 
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Figure 14. Chromatogram of abotulinumtoxinA (Dysport
® Lot #710A) reaction solution 
with SYNTAXtide
®560 substrate (serotype C substrate) exemplifying the 
abotulinumtoxinA BoNT/A drug product does not cleave serotype C substrate. 
 
Trypsin also produced three (3) reaction products that corresponded to the retention times of the 
incobotulinumtoxinA reaction products, however at different ratios (see Figure 15).  
Figure 15. Chromatogram of trypsin reaction solution with SYNTAXtide
®560 substrate 
(serotype C substrate) demonstrating trypsin cleavage pattern for serotype C substrate. 
 
For trypsin, the peaks eluting at 10.3 and 15.7 minutes were the largest, with a smaller peak at 
eluting 3.5 minutes. Serotype C light-chain generated a single peak eluting at 10.4 minutes (see   
Figure 16).  
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Figure 16. Chromatogram of serotype C light-chain reaction solution with 
SYNTAXtide
®560 substrate (serotype C substrate) demonstrating typical serotype C 
cleavage pattern against serotype C substrate. 
 
A summary of the cleavage patterns observed using the SYNTAXtide
®560 substrate is given in 
Table 5. It should be noted that the peak eluting at 8.5 minutes observed in all the chromatograms 
(labeled as reaction impurity) is from an impurity in one of the reaction components. 
Table 5. Summary of cleavage products observed with SYNTAXtide
®560 substrate 
(serotype C substrate) for drug products and control enzymes. 
  Retention Time 
3.5 minutes  10.3 minutes  15.7 minutes 
onabotulinumtoxinA Non-detected Non-detected  Non-detected 
abotulinumtoxinA Non-detected Non-detected  Non-detected 
incobotulinumtoxinA Major  peak  Minor peak  Minor peak 
Serotype C light-chain  Non-detected Major  peak  Non-detected 
Trypsin Minor  peak  Major peak  Major peak 
4. Conclusions 
The suitability of the method was exemplified through analysis of three distinct BoNT/A drug 
products. The method was shown to be robust and sensitive as applied to single vials of drug products 
with very different formulations. Light-chain activity ranked abotulinumtoxinA > onabotulinumtoxinA 
> incobotulinumtoxinA. It should be noted that the abotulinumtoxinA product label stated potency as 
500 U, so it was not surprising that it produced more enzymatic activity, whereas the 
incobotulinumtoxinA label claims 100 U, although it consistently assayed significantly lower than the 
other 100 U product (onabotulinumtoxinA).  
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IncobotulinumtoxinA drug product generated a secondary SNAP cleavage product not produced at 
significant levels by any other BoNT/A drug product or BoNT/A bulk toxin tested. Possible 
explanations include damaged BoNT/A or a contaminating protease that cleaves SNAPtide
®520 
substrate at the C-terminal end of arginine (corresponding to SNAP-25 Arg198–Ala199). Based on the 
cleavage site, suspected candidates for a contaminating protease could include endogenous   
cell-derived trypsin-like protease or toxin co-expression during fermentation (serotype C and A 
behavior). We eliminated co-expression of serotype C as a plausible explanation because while 
serotype C light-chain cleaves SYNTAXtide
®560 it does not cleave SNAPtide
®520 (supplier 
information verified by data on file) and therefore would not produce the T fragment. Another 
explanation is that the type-A holotoxin is damaged during processing and/or degraded during storage, 
thereby altering its proteolytic behavior [10]. To our knowledge, this is the first reported observation of 
this unusual behavior related to a BoNT/A toxin. In addition, older lots of incobotulinumtoxinA 
consistently exhibited lower light-chain activity (type-A cleavage) when compared to newer lots, 
combined with an increase in the ratio of secondary substrate cleavage product to primary cleavage 
product (see Figure 9); suggesting the incobotulinumtoxinA drug product may be degrading   
during storage. 
While the origin and nature of the secondary substrate cleavage produced by incobotulinumtoxinA 
is unknown, a difference in the proteolytic mechanism was elucidated by this study. This difference 
was observed when drug product samples were analyzed without reduction with DTT. In order for 
BoNT/A light-chain activity to occur, the disulfide link between the 100-kD heavy-chain and the   
50-kD light-chain must be reduced. As expected, no BoNT/A cleavage product (SNAPtide
®529) was 
observed without reduction in any samples. However incobotulinumtoxinA samples generated the 
secondary fragment in the absence of a reduction step, consistent with a different proteolytic 
mechanism. In any event it seems evident that some enzymatic activity is directed to the secondary 
mechanism and may also be contributing to loss during storage; e.g., a degrative contaminant protease. 
In an expanded experiment, incobotulinumtoxinA demonstrated cleavage of a BoNT/C substrate 
that was not observed in the other BoNT/A drug products tested. The cleavage pattern of the BoNT/C 
substrate by incobotulinumtoxinA was inconsistent with that of trypsin and BoNT/C light-chain. It is 
interesting to note that this is the only drug product utilizing the naked 150-kD holotoxin. A 
comprehensive understanding of BoNT/A drug product differentiation would benefit from additional 
investigation into this phenomenon now that a tool exists to detect and measure it. 
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